PDCD1 and neoplasm: These findings were in line with recent studies which have shown that immune abnormalities play an important role in tumor evasion, and provide rationale for the use of immune checkpoint inhibitors such as PD‐1 and CLTA‐4 inhibitors for the treatment of PTCL patients.22